Latest P/E ratio for Portage Biotech: -0.02 — see history and peer comparisons.
Get informed when a big investor buys or sells
+ Follow-0.02
The P/E ratio compares a company's stock price to its earnings per share. A lower P/E ratio may indicate that the stock is undervalued.
Portage Biotech's p/e ratio stands at -0.02. That is below the Energy sector average of 16.91. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.
Portage Biotech sits lower the Energy benchmark (16.91) with a P/E ratio of -0.02. That is roughly 100.1% below the sector mean. Peer context matters because what looks expensive or cheap in absolute terms can be normal for the sector.
Whether -0.02 is attractive depends on Portage Biotech's earnings outlook, competitive position, and how peers are valued. Investors typically ask: is growth accelerating, are margins stable, and is the multiple expanding or compressing over time? The history and comparison charts below are built for those checks.
The history chart shows how Portage Biotech's P/E ratio evolved across reporting periods, while the comparison chart places PRTG next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.
Yes — within Energy, P/E ratio is commonly used to spot outliers. Portage Biotech's reading of -0.02 (sector avg 16.91) is a starting point; confirm whether differences come from growth, margins, accounting choices, or one-time items before treating an outlier as a buy or sell signal.